Shopping Cart

0 item(s)--$0.00

γ-Secretase Inhibitor BMS-708163 (Avagacestat)

Chemical Name:  (R)-2-(4-chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide

Molecular Weight:









     DMSO up to 100mM


     Powder:  4oC 1 year

     DMSO:  4oC  3 month

                    -20oC 1 year

BMS-708163 (Avagacestat)

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Availability: In stock

Product Name Catalog No. Amount Price Qty
BMS-708163 (Avagacestat) M60032-2s 2 mg solid
BMS-708163 (Avagacestat) M60032-2 10 mM in DMSO (0.385 mL)
BMS-708163 (Avagacestat) M60032-b Bulk Request - Bulk Inquiry


Biological Activity:

BMS-708163 (Avagacestat) is a potent, selective and orally bioavailable γ-secretase inhibitor with an IC50 of 0.3 nM for APP cleavage. It is 190-fold more selective for APP than Notch, having an IC50 of 58 nM for Notch. Phase I clinical trial studies showed that in humans, BMS-708163 decreased CSF Aβ40 and Aβ42 approximately 30% following daily dose of 100 mg after 28 days and by 60% at daily dose of 150 mg.


How to Use:

In vitro:  BMS-708163 was used at 1-10 µM in vitro.

In vivo: BMS-708163 was dosed orally in female rats at 10 and 100 mg/kg once per day, and could significantly reduced both plasma and brain Aβ40 levels relative to control for the entire dosing interval.



  1. 1.  Gillman K, et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. (2010) ACS Med. Chem. Lett., 1 (3), pp 120–124
  2. 2.  Mitani Y, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. (2012) J Neurosci. 32(6):2037-50.


Product Specification           Product MSDS

Products are for research use only. Not for human use.